FR08C0039I1 - - Google Patents

Info

Publication number
FR08C0039I1
FR08C0039I1 FR08C0039C FR08C0039I1 FR 08C0039 I1 FR08C0039 I1 FR 08C0039I1 FR 08C0039 C FR08C0039 C FR 08C0039C FR 08C0039 I1 FR08C0039 I1 FR 08C0039I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22094096&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR08C0039(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR08C0039I1 publication Critical patent/FR08C0039I1/fr
Application granted granted Critical
Publication of FR08C0039I2 publication Critical patent/FR08C0039I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/24—Camphidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
FR08C0039C 1997-12-31 2008-07-21 Composes azapolycycliques fusionnes avec un aryle Active FR08C0039I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7024597P 1997-12-31 1997-12-31
PCT/IB1998/001813 WO1999035131A1 (en) 1997-12-31 1998-11-13 Aryl fused azapolycyclic compounds

Publications (2)

Publication Number Publication Date
FR08C0039I1 true FR08C0039I1 (cg-RX-API-DMAC10.html) 2008-11-14
FR08C0039I2 FR08C0039I2 (fr) 2009-12-18

Family

ID=22094096

Family Applications (1)

Application Number Title Priority Date Filing Date
FR08C0039C Active FR08C0039I2 (fr) 1997-12-31 2008-07-21 Composes azapolycycliques fusionnes avec un aryle

Country Status (51)

Country Link
US (6) US6410550B1 (cg-RX-API-DMAC10.html)
EP (2) EP1044189B2 (cg-RX-API-DMAC10.html)
JP (1) JP3550359B2 (cg-RX-API-DMAC10.html)
KR (1) KR100408138B1 (cg-RX-API-DMAC10.html)
CN (2) CN1324013C (cg-RX-API-DMAC10.html)
AP (1) AP1170A (cg-RX-API-DMAC10.html)
AR (1) AR017967A1 (cg-RX-API-DMAC10.html)
AT (1) ATE386024T1 (cg-RX-API-DMAC10.html)
AU (1) AU753389C (cg-RX-API-DMAC10.html)
BG (1) BG65058B1 (cg-RX-API-DMAC10.html)
BR (2) BR9814592B1 (cg-RX-API-DMAC10.html)
CA (1) CA2316921C (cg-RX-API-DMAC10.html)
CO (1) CO4810373A1 (cg-RX-API-DMAC10.html)
CY (2) CY1107391T1 (cg-RX-API-DMAC10.html)
CZ (1) CZ301925B6 (cg-RX-API-DMAC10.html)
DE (2) DE122008000038I1 (cg-RX-API-DMAC10.html)
DK (1) DK1044189T4 (cg-RX-API-DMAC10.html)
DZ (1) DZ2697A1 (cg-RX-API-DMAC10.html)
EA (1) EA003190B1 (cg-RX-API-DMAC10.html)
EG (1) EG23816A (cg-RX-API-DMAC10.html)
ES (1) ES2301210T5 (cg-RX-API-DMAC10.html)
FR (1) FR08C0039I2 (cg-RX-API-DMAC10.html)
GT (2) GT199800200AA (cg-RX-API-DMAC10.html)
HN (1) HN1998000177A (cg-RX-API-DMAC10.html)
HR (2) HRP20000445B1 (cg-RX-API-DMAC10.html)
HU (2) HU230297B1 (cg-RX-API-DMAC10.html)
IL (2) IL136727A0 (cg-RX-API-DMAC10.html)
IS (1) IS5514A (cg-RX-API-DMAC10.html)
LU (1) LU91442I2 (cg-RX-API-DMAC10.html)
MA (1) MA26589A1 (cg-RX-API-DMAC10.html)
ME (1) ME00459B (cg-RX-API-DMAC10.html)
MY (1) MY118163A (cg-RX-API-DMAC10.html)
NL (1) NL300355I2 (cg-RX-API-DMAC10.html)
NO (2) NO319115B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ504482A (cg-RX-API-DMAC10.html)
OA (1) OA11428A (cg-RX-API-DMAC10.html)
PA (1) PA8463901A1 (cg-RX-API-DMAC10.html)
PE (1) PE20000053A1 (cg-RX-API-DMAC10.html)
PL (1) PL209404B1 (cg-RX-API-DMAC10.html)
PT (1) PT1044189E (cg-RX-API-DMAC10.html)
RS (1) RS50069B (cg-RX-API-DMAC10.html)
SA (1) SA99191123B1 (cg-RX-API-DMAC10.html)
SG (1) SG102686A1 (cg-RX-API-DMAC10.html)
SI (1) SI1044189T2 (cg-RX-API-DMAC10.html)
SK (1) SK286886B6 (cg-RX-API-DMAC10.html)
TN (1) TNSN98237A1 (cg-RX-API-DMAC10.html)
TR (1) TR200001840T2 (cg-RX-API-DMAC10.html)
TW (1) TW513412B (cg-RX-API-DMAC10.html)
UA (1) UA66825C2 (cg-RX-API-DMAC10.html)
WO (1) WO1999035131A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA9811911B (cg-RX-API-DMAC10.html)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9814592B1 (pt) * 1997-12-31 2010-06-01 composto azapolicìclico condensado com arila, composição farmacêutica contendo o mesmo e seu uso na fabricação de um medicamento.
US6605610B1 (en) * 1997-12-31 2003-08-12 Pfizer Inc Aryl fused azapolycyclic compounds
US8188043B2 (en) 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
DE60040293D1 (de) 1999-07-28 2008-10-30 Univ R Verwendung von nikotin in der angiogenese und der vaskulogenese
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US20020010192A1 (en) * 2000-06-02 2002-01-24 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20020016334A1 (en) * 2000-07-31 2002-02-07 Coe Jotham Wadsworth Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
PT1383733E (pt) * 2001-04-20 2008-04-15 Pfizer Prod Inc Processo para a preparação de indenos 1,3-substituídos e compostos azapolicíclicos fundidos com arilo
KR20040008175A (ko) 2001-05-14 2004-01-28 화이자 프로덕츠 인크. 5,8,14-트리아자테트라시클로(10.3.1.02,11.04,9)-헥사데카-2(11),3,5,7,9-펜타엔의 시트르산염 및 그의 제약 조성물
HRP20030910B1 (hr) * 2001-05-14 2011-11-30 Pfizer Products Inc. Tartaratne soli 5,8,14-triazatetraciklo {10.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>}-heksadeka-2(11), 3,5,7,9-pentaena i pripadajućih farmaceutskih spojeva
DE60209929T2 (de) 2001-11-29 2006-11-16 Pfizer Products Inc., Groton Succinatsalze von 58;8;14-triatetracyclo[10.3.1.0 2,11 .0 4,9]-hexadeca-2,11,3,5,7,9,-pentaen und pharmazeutische zusammensetzungen
EP1448235B1 (en) * 2001-11-30 2007-03-14 Pfizer Products Inc. Oral controlled release pharmaceutical compositions of 5,8,14-triazatetracyclo 10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene
EP1451202B1 (en) 2001-11-30 2008-08-20 Pfizer Products Inc. Aryl fused azapolycyclic compounds
ATE505201T1 (de) * 2002-02-14 2011-04-15 Univ Leland Stanford Junior Enzymbehandlung von nahrungsmitteln für zöliakie- sprue
US8143210B2 (en) * 2002-02-14 2012-03-27 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
US7320788B2 (en) * 2002-02-14 2008-01-22 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for Celiac Sprue
US7202216B2 (en) * 2002-05-14 2007-04-10 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US7462688B2 (en) * 2002-05-14 2008-12-09 The Board Of Trustees Of The Leland Stanford Junior University Peptides for diagnostic and therapeutic methods for celiac sprue
AU2003234634A1 (en) * 2002-05-14 2003-12-02 Felix Hausch Drug therapy for celiac sprue
US7265093B2 (en) * 2002-05-14 2007-09-04 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for Celiac Sprue
DK1565421T3 (da) 2002-11-20 2008-09-22 Pfizer Prod Inc Fremgangsmåde til fremstilling af indan -1,3-dicarboxylsyre
ATE554392T1 (de) * 2002-11-20 2012-05-15 Univ Leland Stanford Junior Diagnoseverfahren für sprue/zöliakie
WO2004048318A1 (en) * 2002-11-25 2004-06-10 Pfizer Products Inc. Improved process for the preparation of 1,3-substituted indenes
JP2006517202A (ja) * 2003-01-15 2006-07-20 ファイザー・プロダクツ・インク アリール縮合多環式ラクタムの製造のための方法
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20040224963A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
JP2006528237A (ja) * 2003-05-20 2006-12-14 ファイザー・プロダクツ・インク バレニクリンの医薬組成物
DK1638971T3 (da) * 2003-06-04 2008-10-27 Pfizer Prod Inc Fremstilling af substitueret Quinoxaliner fra dianilinen med 2,3-dihydroxy-1,4-dioxan
DE602004023299D1 (de) 2003-07-21 2009-11-05 Pfizer Prod Inc Nikotin abhängigkeit reduzierende heteroaryl kondensierte azapolycyclische verbindungen
MXPA06000892A (es) * 2003-07-21 2006-03-30 Pfizer Prod Inc Compuestos azapoliciclicos arilo fusionados.
US20050043406A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US7579313B2 (en) * 2003-11-18 2009-08-25 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
US7563864B2 (en) * 2004-04-26 2009-07-21 Celiac Sprue Research Foundation Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten
US7628985B2 (en) * 2004-04-26 2009-12-08 The Board Of Regents Of The Leland Stanford Junior University Therapeutic enzyme formulations and uses thereof in celiac sprue and/or dermatitis herpetoformis
US7534426B2 (en) * 2004-04-26 2009-05-19 The Board Of Trustees Of The Leland Stanford Junior University Glutenase enzyme assays
WO2006006071A1 (en) * 2004-07-07 2006-01-19 Pfizer Products Inc. Resolution of an aryl-fused azapolycyclic compound
US7766018B2 (en) 2004-09-30 2010-08-03 Smoke-Break, Inc. Device and composition for reducing the incidence of tobacco smoking
JP2008531540A (ja) * 2005-02-24 2008-08-14 ファイザー・プロダクツ・インク 高純度置換キノキサリンの調製
US20060211649A1 (en) * 2005-03-21 2006-09-21 Eric Marchewitz Use of cytisine for enhancing physical performance
US20100048713A1 (en) * 2006-01-06 2010-02-25 Aarhus Universitet Compounds acting on the serotonin transporter
BRPI0709268A2 (pt) * 2006-03-27 2011-06-28 Pfizer Prod Inc padrão de vareniclina e controles de impureza
BRPI0710914A2 (pt) * 2006-04-24 2011-09-27 Pfizer Prod Inc forma de dosagem e método para o tratamento de dependência, adição e supressão de nicotina, em particular para uso na terapia para parar de fumar
US20100234349A1 (en) 2006-09-04 2010-09-16 Olsen Gunnar M Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
RU2009116260A (ru) * 2006-11-09 2010-11-10 Пфайзер Продактс Инк. (Us) Полиморфные модификации никотиновых промежуточных продуктов
WO2008115411A1 (en) * 2007-03-16 2008-09-25 The Board Of Trustees Of The Leland Stanford Junior University Combination enzyme therapy for digestion of dietary gluten
WO2009034431A2 (en) 2007-09-10 2009-03-19 Pfizer Inc. Controlled-release dosage forms for varenicline
WO2009101185A2 (en) * 2008-02-15 2009-08-20 Medichem, S.A. A NEW POLYMORPHIC FORM OF A PYRAZINO[2,3-h][3] BENZAZEPINE DERIVATIVE
US20090215787A1 (en) * 2008-02-22 2009-08-27 Mai De Ltd. Preparations of new polymorphic forms of varenicline tartrate
US9463190B2 (en) 2008-03-31 2016-10-11 University Of South Florida Methods of treating disease-induced ataxia and non-ataxic imbalance
EP2268639A2 (en) 2008-05-22 2011-01-05 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
US20090318460A1 (en) * 2008-05-26 2009-12-24 Glenmark Amorphous varenicline tartrate and process for the preparation thereof
US20090318695A1 (en) * 2008-06-19 2009-12-24 Vinod Kumar Kansal Processes for the preparation of varenicline and intermediates thereof
US20100010221A1 (en) * 2008-07-10 2010-01-14 Revital Lifshitz-Liron Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
EP2334679A1 (en) * 2008-09-01 2011-06-22 Actavis Group PTC EHF Process for preparing varenicline, varenicline intermediates, and pharmaceutically acceptable salts thereof
EP2204369A1 (en) 2008-12-22 2010-07-07 Medichem, S.A. Process for preparing varenicline and intermediates for use therein
SG173639A1 (en) * 2009-02-11 2011-09-29 Sunovion Pharmaceuticals Inc Histamine h3 inverse agonists and antagonists and methods of use thereof
US20120093887A1 (en) 2009-06-10 2012-04-19 Actavis Group Ptc Ehf Amorphous varenicline tartrate co-precipitates
RU2012102052A (ru) 2009-06-22 2013-11-20 Тева Фармасьютикал Индастриз Лтд. Твердые формы солей варениклина и способы их получения
JP2013504581A (ja) * 2009-09-11 2013-02-07 スノヴィオン ファーマシューティカルズ インコーポレイテッド ヒスタミンｈ３インバースアゴニストおよびアンタゴニストとその使用方法
WO2011110954A1 (en) 2010-03-09 2011-09-15 Actavis Group Ptc Ehf Highly pure varenicline or a pharmaceutically acceptable salt thereof substantially free of methylvarenicline impurity
KR101109389B1 (ko) * 2010-04-30 2012-01-30 삼성전기주식회사 인쇄회로기판 및 그 제조방법
WO2011140431A1 (en) 2010-05-06 2011-11-10 Teva Pharmaceutical Industries Ltd. Varenicline salts and crystal forms thereof
US20120004239A1 (en) 2010-06-11 2012-01-05 Medichem, S.A. Process for Preparing Quinoxaline Derivatives
MX2013013326A (es) 2011-06-30 2014-02-27 Toray Industries Agente antipruritico.
ITMI20111413A1 (it) 2011-07-28 2013-01-29 Dipharma Francis Srl Procedimento per la preparazione di vareniclina
ES2426517B1 (es) 2012-04-20 2014-05-14 Genetracer Biotech S.L Método para predecir la seguridad de un tratamiento farmacológico
ES2426838B1 (es) 2012-04-20 2014-05-07 Genetracer Biotech S.L Método para predecir el éxito en el abandono del consumo de tabaco en respuesta a un tratamiento farmacológico
CN103570502A (zh) * 2012-07-18 2014-02-12 上海科胜药物研发有限公司 一种伐伦克林中间体的制备方法
US9636340B2 (en) 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
CN103992272B (zh) * 2014-06-09 2016-05-11 安徽省逸欣铭医药科技有限公司 一种盐酸喷他佐辛酯、其制备方法及其用途
KR20160126697A (ko) 2015-04-24 2016-11-02 한미정밀화학주식회사 신규 결정형의 바레니클린 옥살산 염 수화물, 이의 제조방법, 및 이를 포함하는 약학 조성물
KR20160143407A (ko) 2015-06-05 2016-12-14 한미정밀화학주식회사 신규한 바레니클린 뮤케이트 염, 이의 결정형 및 이의 제조방법
KR101724301B1 (ko) 2016-11-22 2017-04-10 주식회사 한서켐 바레니클린 살리실산염의 i형 결정 및 그 제조방법
CN106674194B (zh) * 2016-12-14 2019-03-05 山东省联合农药工业有限公司 一种结构新颖的烟碱类杀虫剂及其制备方法和用途
WO2018160043A1 (ko) 2017-03-03 2018-09-07 주식회사 씨티씨바이오 바레니클린 또는 이의 약학적으로 허용가능한 염의 포접 복합체를 포함하는 구강 투여용 제제
KR102463733B1 (ko) 2017-06-30 2022-11-04 한미약품 주식회사 함량 균일성 및 안정성이 향상된 바레니클린 옥살산염이 포함된 약제학적 조성물
WO2018154395A2 (en) 2018-06-11 2018-08-30 Alvogen Malta Operations (Row) Ltd Controlled release pharmaceutical composition of varenicline
KR20200034293A (ko) 2018-09-21 2020-03-31 한미약품 주식회사 제어 방출용 바레니클린 제제
WO2021222230A1 (en) 2020-04-28 2021-11-04 Oyster Point Pharma, Inc. Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections
CN113956255A (zh) * 2020-07-20 2022-01-21 威智医药有限公司 一种伐尼克兰中间体、伐尼克兰及其盐的制备方法
US11040983B1 (en) 2020-08-14 2021-06-22 Almatica Pharma Llc Cocrystal of varenicline and oxalic acid, pharmaceutical composition thereof, and methods of use thereof
WO2022035434A1 (en) 2020-08-14 2022-02-17 Almatica Pharma Llc Cocrystal of varenicline and oxalic acid, pharmaceutical composition thereof, and methods of use thereof
WO2022147189A1 (en) * 2020-12-30 2022-07-07 Antares Pharma, Inc. Varenicline prodrugs
WO2022222019A1 (en) * 2021-04-20 2022-10-27 Suzhou Fude Zhaofeng Biochemical Technology Co., Ltd Total synthesis of varenicline
CN113277993B (zh) * 2021-06-06 2023-07-21 湖南第一师范学院 一种Tafamidis及其衍生物的合成方法
US20250134904A1 (en) 2021-12-23 2025-05-01 Medichem, S.A. Solid pharmaceutical formulations of varenicline
US11602537B2 (en) 2022-03-11 2023-03-14 Par Pharmaceutical, Inc. Varenicline compound and process of manufacture thereof
EP4241775A1 (en) 2022-03-11 2023-09-13 Par Pharmaceutical, Inc. Tablet comprising varenicline and process of preparation thereof
WO2023244574A1 (en) 2022-06-14 2023-12-21 Amygdala Neurosciences, Inc. Aldh-2 inhibitor compounds and methods of use
EP4611896A1 (en) 2022-11-04 2025-09-10 Pfizer Inc. Prodrugs of varenicline and compounds containing vulnerable amines
IT202300003888A1 (it) 2023-03-03 2024-09-03 Dipharma Francis Srl Processo di preparazione di un farmaco usato per trattare la dipendenza da nicotina
WO2024224270A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Varenicline formulations

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471503A (en) * 1967-05-05 1969-10-07 Mcneilab Inc 1,2,3,5,6,7-hexahydro-4-phenethyl-2,6-methano-4h-4- benzazonin-12-ols
CH644116A5 (de) * 1980-08-21 1984-07-13 Hoffmann La Roche Imidazolderivate.
EP0853621A1 (en) * 1995-09-22 1998-07-22 Novo Nordisk A/S Novel substituted azacyclic or azabicyclic compounds
US6605610B1 (en) * 1997-12-31 2003-08-12 Pfizer Inc Aryl fused azapolycyclic compounds
BR9814592B1 (pt) * 1997-12-31 2010-06-01 composto azapolicìclico condensado com arila, composição farmacêutica contendo o mesmo e seu uso na fabricação de um medicamento.
AU1918299A (en) * 1998-02-23 1999-09-06 Warner-Lambert Company Substituted quinoxaline derivatives as interleukin-8 receptor antagonists
EP0955301A3 (en) * 1998-04-27 2001-04-18 Pfizer Products Inc. 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors
SK15952000A3 (sk) * 1998-04-29 2002-06-04 Pfizer Products Inc. Aryl-anelovaná azapolycyklická zlúčenina, jej použitie a farmaceutické kompozície na jej báze
EP1359152B1 (en) * 1999-01-29 2008-05-07 Abbott Laboratories Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands
FR2788982B1 (fr) * 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
HRP20030910B1 (hr) * 2001-05-14 2011-11-30 Pfizer Products Inc. Tartaratne soli 5,8,14-triazatetraciklo {10.3.1.0<sup>2,11</sup>.0<sup>4,9</sup>}-heksadeka-2(11), 3,5,7,9-pentaena i pripadajućih farmaceutskih spojeva
KR20040008175A (ko) * 2001-05-14 2004-01-28 화이자 프로덕츠 인크. 5,8,14-트리아자테트라시클로(10.3.1.02,11.04,9)-헥사데카-2(11),3,5,7,9-펜타엔의 시트르산염 및 그의 제약 조성물
DE60209929T2 (de) * 2001-11-29 2006-11-16 Pfizer Products Inc., Groton Succinatsalze von 58;8;14-triatetracyclo[10.3.1.0 2,11 .0 4,9]-hexadeca-2,11,3,5,7,9,-pentaen und pharmazeutische zusammensetzungen
EP1448235B1 (en) * 2001-11-30 2007-03-14 Pfizer Products Inc. Oral controlled release pharmaceutical compositions of 5,8,14-triazatetracyclo 10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene
EP1451202B1 (en) * 2001-11-30 2008-08-20 Pfizer Products Inc. Aryl fused azapolycyclic compounds
MXPA06000892A (es) * 2003-07-21 2006-03-30 Pfizer Prod Inc Compuestos azapoliciclicos arilo fusionados.

Also Published As

Publication number Publication date
DZ2697A1 (fr) 2003-03-29
CY2008013I1 (el) 2009-11-04
TW513412B (en) 2002-12-11
AU753389B2 (en) 2002-10-17
YU40300A (sh) 2003-10-31
CN1285821A (zh) 2001-02-28
LU91442I2 (fr) 2008-07-21
EP1044189A1 (en) 2000-10-18
IL136727A0 (en) 2001-06-14
CN1324013C (zh) 2007-07-04
HRP20000445A2 (en) 2001-04-30
HUP0100949A2 (hu) 2001-08-28
EG23816A (en) 2007-09-19
US6897310B2 (en) 2005-05-24
HK1031878A1 (en) 2001-06-29
FR08C0039I2 (fr) 2009-12-18
PT1044189E (pt) 2008-04-22
AR017967A1 (es) 2001-10-24
KR20010033823A (ko) 2001-04-25
DE69839131T3 (de) 2015-05-07
JP3550359B2 (ja) 2004-08-04
ATE386024T1 (de) 2008-03-15
AU9641698A (en) 1999-07-26
OA11428A (en) 2004-05-03
EA003190B1 (ru) 2003-02-27
DE69839131T2 (de) 2009-02-05
US20020111350A1 (en) 2002-08-15
NO2006016I1 (no) 2006-11-27
KR100408138B1 (ko) 2003-12-01
CY2008013I2 (el) 2009-11-04
BR9816186B1 (pt) 2009-01-13
CY1107391T1 (el) 2010-07-28
DE122008000038I1 (de) 2008-11-13
NO20003422L (no) 2000-08-29
ZA9811911B (en) 2000-06-29
BG65058B1 (bg) 2007-01-31
US20020132824A1 (en) 2002-09-19
MA26589A1 (fr) 2004-12-20
CA2316921C (en) 2004-12-07
SA99191123B1 (ar) 2006-10-02
CN1715280A (zh) 2006-01-04
US20020072525A1 (en) 2002-06-13
US6887884B2 (en) 2005-05-03
NL300355I1 (nl) 2008-08-01
EP1659114A3 (en) 2007-01-17
HUS1600018I1 (hu) 2018-05-02
US6951938B2 (en) 2005-10-04
ES2301210T3 (es) 2008-06-16
ES2301210T5 (es) 2015-05-07
NO319115B1 (no) 2005-06-20
DE69839131D1 (de) 2008-03-27
HRP20050506A2 (en) 2006-03-31
EP1044189B2 (en) 2015-02-25
SI1044189T2 (sl) 2015-05-29
IL136727A (en) 2006-06-11
LU91442I9 (cg-RX-API-DMAC10.html) 2018-12-31
HUP0100949A3 (en) 2002-12-28
DK1044189T4 (en) 2015-03-30
NZ504482A (en) 2003-01-31
EA200000592A1 (ru) 2000-12-25
EP1044189B1 (en) 2008-02-13
CO4810373A1 (es) 1999-06-30
HN1998000177A (es) 1999-02-09
SG102686A1 (en) 2004-03-26
PE20000053A1 (es) 2000-02-07
WO1999035131A1 (en) 1999-07-15
IS5514A (is) 2000-05-26
AP9801422A0 (en) 1998-12-31
SK9712000A3 (en) 2002-03-05
PA8463901A1 (es) 2000-09-29
BG104561A (en) 2001-01-31
AU753389C (en) 2007-08-09
TR200001840T2 (tr) 2000-12-21
PL341824A1 (en) 2001-05-07
JP2002500218A (ja) 2002-01-08
AP1170A (en) 2003-06-30
NL300355I2 (nl) 2008-11-03
NO20003422D0 (no) 2000-06-30
CA2316921A1 (en) 1999-07-15
US6410550B1 (en) 2002-06-25
CZ20002438A3 (cs) 2002-11-13
GT199800200A (es) 2000-06-07
NO2006016I2 (cg-RX-API-DMAC10.html) 2008-10-20
US20020072524A1 (en) 2002-06-13
HRP20000445B1 (hr) 2009-04-30
CZ301925B6 (cs) 2010-08-04
BR9814592A (pt) 2000-10-17
DK1044189T3 (da) 2008-05-13
HU230297B1 (hu) 2015-12-28
PL209404B1 (pl) 2011-08-31
GT199800200AA (es) 2000-06-07
US20070275973A1 (en) 2007-11-29
BR9814592B1 (pt) 2010-06-01
TNSN98237A1 (fr) 2005-03-15
ME00459B (me) 2011-10-10
RS50069B (sr) 2009-01-22
UA66825C2 (uk) 2004-06-15
SI1044189T1 (sl) 2008-06-30
EP1659114A2 (en) 2006-05-24
SK286886B6 (sk) 2009-07-06
MY118163A (en) 2004-09-30

Similar Documents

Publication Publication Date Title
BE2018C032I2 (cg-RX-API-DMAC10.html)
LU91442I9 (cg-RX-API-DMAC10.html)
CH0944937H2 (cg-RX-API-DMAC10.html)
ITMI970390V0 (cg-RX-API-DMAC10.html)
ITTO970411A0 (cg-RX-API-DMAC10.html)
ITMI971197A0 (cg-RX-API-DMAC10.html)
ITMI971092A0 (cg-RX-API-DMAC10.html)
BE2013C047I2 (cg-RX-API-DMAC10.html)
ITMI971427A0 (cg-RX-API-DMAC10.html)
IN191791B (cg-RX-API-DMAC10.html)
IN186649B (cg-RX-API-DMAC10.html)
IN185765B (cg-RX-API-DMAC10.html)
IN185465B (cg-RX-API-DMAC10.html)
BR9700653A (cg-RX-API-DMAC10.html)
ITVR970024V0 (cg-RX-API-DMAC10.html)
ITRM970147V0 (cg-RX-API-DMAC10.html)
ITRM970387A0 (cg-RX-API-DMAC10.html)
CN3057976S (cg-RX-API-DMAC10.html)
CN3056419S (cg-RX-API-DMAC10.html)
CN3058000S (cg-RX-API-DMAC10.html)
CN3057997S (cg-RX-API-DMAC10.html)
CN3058057S (cg-RX-API-DMAC10.html)
CN3058088S (cg-RX-API-DMAC10.html)
CN3057977S (cg-RX-API-DMAC10.html)
CN3058138S (cg-RX-API-DMAC10.html)